This hypothesis was supported by our observation that abrogating the generation of functional MDSCs improved the therapeutic efficacy of anti-PD-L1 in an ICB-resistant mouse tumor model.4 Other interventions, including type I IFNs and TNF-α, might also help provide favorable conditions to form a positive feedback loop for T-cell activation in ICB therapy. This evidence concerns the gene TNF and neoplasm.